Grandfield & Dodd’s Iovance Biotherapeutics IOVA Stock Holding History

Grandfield & Dodd’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$260K	Buy	62,520 +2,340	+4%	+$8.89K	0.01%	199
2026 Q1	$211K	Sell	60,180 -5,750	-9%	-$18.4K	0.01%	200
2025 Q4	$180K	Sell	65,930 -11,895	-15%	-$27.5K	0.01%	206
2025 Q3	$169K	Sell	77,825 -13,250	-15%	-$31.3K	0.01%	210
2025 Q2	$157K	Buy	91,075 +100	+0.1%	+$249	0.01%	211
2025 Q1	$303K	Buy	90,975 +35,260	+63%	+$182K	0.02%	169
2024 Q4	$412K	Buy	55,715 +25,645	+85%	+$238K	0.03%	151
2024 Q3	$282K	Buy	+30,070	New	+$285K	0.02%	182

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Grandfield & Dodd's IOVA Position: Q2 2026 in Review

Grandfield & Dodd increased its Iovance Biotherapeutics (IOVA) stake by 3.9% in Q2 2026, buying an estimated $8.89K and bringing the position to 62,520 shares worth $260K. The position accounts for 0.01% of the portfolio, ranked #199.

Grandfield & Dodd first reported a position in IOVA in Q3 2024 and has held it in 8 quarters since. The position peaked at $412K in Q4 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Grandfield & Dodd held 62,520 shares of Iovance Biotherapeutics worth $260K as of Q2 2026.
Grandfield & Dodd bought 2,340 Iovance Biotherapeutics shares in Q2 2026, an estimated $8.89K.
Iovance Biotherapeutics made up 0.01% of Grandfield & Dodd's portfolio in Q2 2026, its #199 holding.
Grandfield & Dodd first reported a position in Iovance Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
Grandfield & Dodd's Iovance Biotherapeutics position peaked at $412K in Q4 2024.
293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Grandfield & Dodd's 13F filing for Q2 2026, filed 7 Aug 2026.